» Articles » PMID: 10420154

Relationship of P21(WAF1) Expression with Disease-free Survival and Biochemical Recurrence in Prostate Adenocarcinomas (PCa)

Overview
Journal Prostate
Date 1999 Jul 27
PMID 10420154
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The p21(WAF1) gene is considered to be one of the major regulators of the cell cycle. Its level of expression has been shown to correlate with pathologic stage and Gleason score in prostatic cancer. However, its relationship to clinical outcome is not yet well-characterized.

Methods: Immunohistochemical staining for p21(WAF1) protein expression was performed in 62 consecutive radical prostatectomy specimens from our institution. The results were correlated with the disease-free survival and biochemical recurrence of the patients.

Results: Thirty-four of the 62 patients were Caucasian and 28 were African American. There was a significant correlation between p21(WAF1) expression and biochemical recurrence after radical prostatectomy (P < 0.0095). However, while p21(WAF1) staining in prostate cancer was a prognostic indicator of disease-free survival in Caucasians (P < 0.0001), it appeared not to be a factor in African-American men (P = 0.908).

Conclusions: This study suggests that p21(WAF1) may have a role in the pathogenesis and progression of prostate carcinoma, and may serve as a predictor of biochemical recurrence of this tumor. The differences in the values of p21(WAF1) as a prognostic marker of disease-free survival in Caucasians vs. African Americans suggest that progression of prostate cancer may have different mechanisms in different ethnic groups.

Citing Articles

Pathway-based expression profiling of benign prostatic hyperplasia and prostate cancer delineates an immunophilin molecule associated with cancer progression.

Bhowal A, Majumder S, Ghosh S, Basu S, Sen D, Roychowdhury S Sci Rep. 2017; 7(1):9763.

PMID: 28852180 PMC: 5575002. DOI: 10.1038/s41598-017-10068-9.


Inhibitor of p52 NF-κB subunit and androgen receptor (AR) interaction reduces growth of human prostate cancer cells by abrogating nuclear translocation of p52 and phosphorylated AR(ser81).

Mehraein-Ghomi F, Church D, Schreiber C, Weichmann A, Basu H, Wilding G Genes Cancer. 2015; 6(9-10):428-44.

PMID: 26622945 PMC: 4633170. DOI: 10.18632/genesandcancer.77.


Deletion of p21/Cdkn1a confers protective effect against prostate tumorigenesis in transgenic adenocarcinoma of the mouse prostate model.

Jain A, Raina K, Agarwal R Cell Cycle. 2013; 12(10):1598-604.

PMID: 23624841 PMC: 3680539. DOI: 10.4161/cc.24741.


The AR dependent cell cycle: mechanisms and cancer relevance.

Schiewer M, Augello M, Knudsen K Mol Cell Endocrinol. 2011; 352(1-2):34-45.

PMID: 21782001 PMC: 3641823. DOI: 10.1016/j.mce.2011.06.033.


Androgen suppresses proliferation of castration-resistant LNCaP 104-R2 prostate cancer cells through androgen receptor, Skp2, and c-Myc.

Chuu C, Kokontis J, Hiipakka R, Fukuchi J, Lin H, Lin C Cancer Sci. 2011; 102(11):2022-8.

PMID: 21781227 PMC: 3200457. DOI: 10.1111/j.1349-7006.2011.02043.x.